CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Cochlear implantdevice
Likely dose
Cochlear implant at poor ear, continued hearing aid at better earAI-extracted
Key inclusion· 12
  • Age 18 years or older
  • Native English speaker
  • Desire for functional binaural hearing
  • Failed previous BiCROS or hearing aid trial for asymmetric hearing loss, or willing to complete trial
Key exclusion· 5
  • Medical condition that contraindicates surgery
  • Currently using implantable device in ear to be implanted
  • Cochlear malformation or obstruction precluding full electrode array insertion
  • Hearing loss of neural or central origin

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03052920
NCT03052920N/ACompleted

Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial

Washington University School of Medicine·interventional·Posted Feb 14, 2017·Updated Mar 11, 2026

In Brief

A clinical study evaluating Cochlear implant for Hearing Loss. Completed, enrolled 40 participants across 4 sites.

Detailed Summary

This longitudinal study evaluates the possible benefit of cochlear implantation in the poor ear of adults with asymmetric hearing loss who continue to use a hearing aid in the better hearing ear.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 14, 2017
Enrollment StartJul 28, 2017
Primary CompletionNov 17, 2020
Study CompletionMar 10, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.4 years ago

Interventions

Cochlear implantdevice

Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.